BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17914094)

  • 1. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy.
    Wu CT; Chen WC; Liao SK; Hsu CL; Lee KD; Chen MF
    Endocr Relat Cancer; 2007 Sep; 14(3):633-43. PubMed ID: 17914094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
    Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer.
    Seki M; Teishima J; Mochizuki H; Mutaguchi K; Yasumoto H; Oka K; Nagamatsu H; Shoji K; Matsubara A
    Hiroshima J Med Sci; 2013 Mar; 62(1):13-9. PubMed ID: 23600329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
    Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
    J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP.
    Xie BX; Zhang H; Yu L; Wang J; Pang B; Wu RQ; Qian XL; Li SH; Shi QG; Wang LL; Zhou JG
    Asian J Androl; 2010 May; 12(3):405-14. PubMed ID: 20118949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
    Stoyanova R; Hachem P; Hensley H; Khor LY; Mu Z; Hammond ME; Agrawal S; Pollack A
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1151-60. PubMed ID: 17637390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
    Li M; Zhang Z; Hill DL; Wang H; Zhang R
    Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.